<DOC>
	<DOCNO>NCT00001029</DOCNO>
	<brief_summary>To compare efficacy , safety tolerance , clinical immunologic effect zidovudine ( AZT ) plus zalcitabine ( dideoxycytidine ; ddC ) , AZT plus didanosine ( ddI ) , AZT alternate monthly ddI measure difference survival among HIV-infected person receive 6 month nucleoside monotherapy CD4 count great equal 50 cells/mm3 . Combining two nucleoside drug theoretical advantage optimal protection evolution resistant strain HIV . However , one major problem combination nucleoside therapy patient advanced disease increase toxicity result therapy . One approach minimize toxicity perhaps retain benefit combination therapy alternate two drug .</brief_summary>
	<brief_title>A Comparison Three Treatments Advanced HIV Disease Patients Who Have Received Nucleoside Therapy Past</brief_title>
	<detailed_description>Combining two nucleoside drug theoretical advantage optimal protection evolution resistant strain HIV . However , one major problem combination nucleoside therapy patient advanced disease increase toxicity result therapy . One approach minimize toxicity perhaps retain benefit combination therapy alternate two drug . Patients randomize one three treatment arm : AZT plus ddI , AZT plus ddC , AZT alone alternate monthly ddI . Half patient receive AZT alternate monthly ddI start AZT , half start ddI . Treatment continue death termination study . Patients follow every 4 week . The study include subset patient virologic , pharmacokinetic , macroneurologic assessment make .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis . Allowed : Erythropoietin . Prophylaxis MAI fungal infection . Antibiotics . Overthecounter , alternative , regularly prescribe drug . Steroids , &lt; 21 day . Concurrent Treatment : Allowed : Radiation therapy cutaneous Kaposi 's sarcoma . Patients must : HIV infection . CD4 count &lt; = 50 cells/mm3 . Prior nucleoside monotherapy least 6 month . Life expectancy least 6 month . Prior Medication : Required : Nucleoside monotherapy least 6 month . Active alcohol drug abuse . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Severe peripheral neuropathy . Psychological emotional problem sufficient prevent study compliance . Concurrent Medication : Excluded : Systemic chemotherapy malignancy . Acute induction therapy opportunistic infection . Patients follow prior condition exclude : History acute chronic pancreatitis . Grade 3 great toxicity AZT , ddI , ddC two occasion . Prior Medication : Excluded : Nonstudy nucleosides biologic response modifier within 7 day prior study entry . Acute therapy opportunistic process within 14 day prior study entry . Acute systemic therapy medical condition within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>